Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 4 studies | 33% ± 14% | |
pericyte | 4 studies | 27% ± 6% |
Insufficient scRNA-seq data for expression of ALKAL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 7292.87 | 258 / 258 | 73% | 44.33 | 169 / 230 |
kidney | 84% | 730.84 | 75 / 89 | 75% | 19.74 | 673 / 901 |
pancreas | 100% | 1533.06 | 328 / 328 | 58% | 7.44 | 103 / 178 |
ovary | 100% | 2874.12 | 180 / 180 | 44% | 4.67 | 190 / 430 |
thymus | 72% | 422.80 | 468 / 653 | 55% | 4.04 | 334 / 605 |
lung | 99% | 1398.90 | 570 / 578 | 21% | 1.40 | 248 / 1155 |
uterus | 87% | 1545.40 | 148 / 170 | 25% | 3.95 | 116 / 459 |
breast | 92% | 1045.37 | 424 / 459 | 10% | 1.98 | 111 / 1118 |
blood vessel | 86% | 1045.20 | 1152 / 1335 | 0% | 0 | 0 / 0 |
spleen | 85% | 495.27 | 204 / 241 | 0% | 0 | 0 / 0 |
adipose | 82% | 933.50 | 990 / 1204 | 0% | 0 | 0 / 0 |
stomach | 73% | 471.32 | 262 / 359 | 4% | 0.16 | 12 / 286 |
intestine | 50% | 181.75 | 482 / 966 | 9% | 0.59 | 49 / 527 |
skin | 48% | 373.99 | 872 / 1809 | 1% | 0.15 | 3 / 472 |
brain | 27% | 123.20 | 701 / 2642 | 19% | 0.89 | 136 / 705 |
bladder | 38% | 135.38 | 8 / 21 | 8% | 0.31 | 38 / 504 |
prostate | 37% | 212.42 | 91 / 245 | 7% | 0.31 | 33 / 502 |
tonsil | 0% | 0 | 0 / 0 | 31% | 1.89 | 14 / 45 |
liver | 11% | 41.19 | 25 / 226 | 17% | 4.55 | 70 / 406 |
esophagus | 13% | 49.32 | 183 / 1445 | 9% | 1.03 | 16 / 183 |
heart | 5% | 15.31 | 41 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 11.02 | 18 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.13 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0070378 | Biological process | positive regulation of ERK5 cascade |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0030298 | Molecular function | receptor signaling protein tyrosine kinase activator activity |
GO_0005515 | Molecular function | protein binding |
GO_0030971 | Molecular function | receptor tyrosine kinase binding |
GO_0030297 | Molecular function | transmembrane receptor protein tyrosine kinase activator activity |
GO_0005125 | Molecular function | cytokine activity |
Gene name | ALKAL2 |
Protein name | ALK and LTK ligand 2 ALK and LTK ligand 2 (Augmentor alpha) (AUG-alpha) |
Synonyms | UNQ542/PRO1097 FAM150B |
Description | FUNCTION: Cytokine that acts as a physiological ligand for receptor tyrosine kinases LTK and ALK, leading to their activation . Cytokine-binding is sufficient to activate LTK . In contrast, ALKAL2-driven activation of ALK is coupled with heparin-binding to ALK . Stimulation of ALK signaling is involved in neural development and regulation of energy expenditure . . |
Accessions | Q6UX46 B5MCG6 H0Y3U4 ENST00000405290.5 ENST00000401489.6 ENST00000344414.9 ENST00000452023.1 B5MC33 ENST00000401503.5 A0A0B4J1W8 ENST00000403610.9 [Q6UX46-1] |